Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Semaglutide Peptide
FDA-approved GLP-1 agonist for diabetes and obesity.
What is Semaglutide?
Semaglutide is a metabolic · incretin peptide studied for type 2 diabetes (ozempic, rybelsus) and obesity / chronic weight management (wegovy). Below is an educational overview of Semaglutide peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Semaglutide in plain language
Semaglutide is an FDA-approved GLP-1 receptor agonist prescribed for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).
- Classification: FDA-approved prescription medication.
- Mechanism: activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, slowing gastric emptying and reducing appetite.
- Administration: once-weekly subcutaneous injection, or once-daily oral tablet as Rybelsus.
- Outcome evidence: the SELECT trial reported reduced major adverse cardiovascular events in adults with cardiovascular disease and overweight or obesity.
- Common adverse effects: nausea, vomiting, diarrhea and constipation, generally worst during dose escalation.
- Boxed warning: thyroid C-cell tumors observed in rodents; contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.
Machine-readable version: /peptide/semaglutide/summary
Plain-Language Label Highlights
Brand names: Ozempic, Wegovy, Rybelsus
Type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy).
A weekly injection (or daily pill) that mimics a gut hormone, lowering blood sugar, slowing digestion, and reducing appetite.
May cause thyroid C-cell tumors in rodents — do not use if you or family have medullary thyroid cancer or MEN 2.
- •Nausea
- •Diarrhea
- •Vomiting
- •Constipation
- •Stomach pain
- •Pancreatitis
- •Gallbladder disease
- •Kidney injury from dehydration
- •Diabetic eye disease progression
- •Low blood sugar (with insulin/sulfonylureas)
- •Personal/family history of medullary thyroid cancer
- •Multiple Endocrine Neoplasia type 2
- •History of pancreatitis (caution)
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Semaglutide Mechanism of Action
A long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central GLP-1 receptors.
Semaglutide Research Areas & Benefits
Semaglutide Dosage & Common Research Protocols
Stepwise dose escalation to manage GI tolerability in approved indications.
Protocols summarized for educational reference from published research. Not dosing guidance.
Semaglutide Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Type 2 diabetes (FDA-approved, Ozempic) | Adults with type 2 diabetes | Once-weekly subcutaneous injection | 0.25 mg starter for 4 weeks, then 0.5 mg; may increase to 1 mg and 2 mg | Ongoing, prescriber-directed | Starter dose is for tolerability, not glycemic effect. Reflects approved prescribing information. |
| Chronic weight management (FDA-approved, Wegovy) | Adults with obesity or overweight plus a weight-related condition | Once-weekly subcutaneous injection | Escalated monthly: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg maintenance | 68-week trial programme; ongoing in practice | STEP-1 reported ~14.9% mean weight reduction at 68 weeks versus ~2.4% with placebo. |
| Oral formulation (Rybelsus) | Adults with type 2 diabetes | Oral tablet, once daily, fasted with ≤120 mL water | 3 mg for 30 days, then 7 mg, optionally 14 mg | Ongoing | Absorption depends on the SNAC carrier and strict fasting conditions. |
Semaglutide — Frequently Asked Questions
What is semaglutide in one sentence?+
Semaglutide is an FDA-approved GLP-1 receptor agonist prescribed for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy), given as a once-weekly injection or a daily tablet.
How much weight loss did semaglutide produce in trials?+
In the STEP-1 trial, adults without diabetes taking semaglutide 2.4 mg weekly lost about 14.9% of body weight at 68 weeks versus about 2.4% on placebo. Results in people with type 2 diabetes (STEP-2) were smaller, near 9.6%.
How does semaglutide work?+
It mimics GLP-1, increasing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite circuits to reduce energy intake.
What are the most common semaglutide side effects?+
Nausea, vomiting, diarrhea, and constipation are the most frequently reported and are usually dose-related and managed with slow titration. Labeling also carries a boxed warning about thyroid C-cell tumors observed in rodents.
Is compounded semaglutide the same as Ozempic or Wegovy?+
No. Compounded preparations are not FDA-evaluated for safety, efficacy, or quality, and the FDA has warned about dosing errors and unapproved salt forms such as semaglutide sodium and semaglutide acetate.
Semaglutide vs tirzepatide — which is stronger?+
In SURMOUNT-5, the one head-to-head trial in adults with obesity and without diabetes, tirzepatide produced roughly 20% mean weight reduction at 72 weeks versus roughly 14% for semaglutide. Both are prescription-only and titrated under clinical supervision.
Semaglutide Studies & Cited Research
Semaglutide for weight loss in adults with overweight or obesity (STEP 1)
Mean ~15% weight loss at 68 weeks versus placebo.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Cardiovascular outcomes with semaglutide (SELECT)
Reduced MACE in adults with CVD and overweight/obesity.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Semaglutide Side Effects & Safety Considerations
- •FDA-approved with established safety profile but real side effects (GI, pancreatitis risk, gallbladder events).
- •Requires physician oversight and prescription.
- •Compounded versions vary in quality.
Common questions about Semaglutide
Research stacks featuring Semaglutide
More Fat loss peptides · See all 14
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Key references for Semaglutide
Primary sources reviewed by the Peptides.cafe research team. Links open the original PubMed record, journal listing, or regulatory notice.
- [1]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1)New England Journal of Medicine · 2021
Pivotal 68-week trial reporting ~14.9% mean weight reduction versus ~2.4% on placebo.
- [2]Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)New England Journal of Medicine · 2023
Reported a 20% reduction in major adverse cardiovascular events in the studied population.
- [3]FDA approves new drug treatment for chronic weight management (Wegovy)U.S. Food & Drug Administration · 2021
Primary regulatory source confirming the approved indication and population.
- [4]FDA alerts about compounded semaglutide productsU.S. Food & Drug Administration · 2023
Documents FDA concerns about unapproved salt forms and dosing errors in compounded supply.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.